Eric Karas, an officer of ARS Pharmaceuticals, Inc., filed a Form 144 notice of proposed sale on October 30, 2026, covering 80,000 shares of common stock to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Proposed sale: 80,000 shares of ARS Pharmaceuticals common stock with an aggregate market value of $270,272.00.
  • Acquisition method: The shares were acquired on October 30, 2026, via a stock option exercise from the issuer, with cash payment on the same date.
  • Shares outstanding: According to the filing, 99,447,343 shares of common stock were outstanding at the time of the notice.
  • Prior sales in past 3 months: Karas sold 100,000 shares on October 19, 2026 (gross proceeds $410,240.00); 100,000 shares on October 1, 2026 (gross proceeds $426,096.77); 100,000 shares on September 30, 2026 (gross proceeds $431,560.00); and 14,064 shares on September 11, 2026 (gross proceeds $69,761.66).
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Exchange: The securities are listed on NASDAQ.

ARS Pharmaceuticals Officer Discloses Proposed Common Stock Sale via Form 144

According to the filing, Eric Karas, identified as an officer of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY is not confirmed in this filing; the filing identifies the exchange as NASDAQ), submitted a Form 144 notice dated October 30, 2026. The notice covers a proposed sale of 80,000 shares of common stock with an aggregate market value of $270,272.00, with an approximate sale date of October 30, 2026. The filing states the shares were acquired through a stock option exercise from the issuer on October 30, 2026, with full cash payment made on the same date.

The filing also discloses Karas's sales of ARS Pharmaceuticals common stock during the three months preceding the notice. Those transactions total 314,064 shares sold across four separate dates: 100,000 shares on October 19, 2026, generating gross proceeds of $410,240.00; 100,000 shares on October 1, 2026, generating gross proceeds of $426,096.77; 100,000 shares on September 30, 2026, generating gross proceeds of $431,560.00; and 14,064 shares on September 11, 2026, generating gross proceeds of $69,761.66. All prior sales listed in the filing were in the same class of common stock and share the same seller address as the issuer's principal office in San Diego, California.

The filing identifies ARS Pharmaceuticals, Inc. with SEC File Number 001-39756, located at 11682 El Camino Real, Suite 300, San Diego, California 92130. The total shares outstanding reported in the filing are 99,447,343. By signing the notice, Karas represented, as stated in the form, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."

What Was Disclosed

ARS Pharmaceuticals officer Eric Karas filed a Form 144 on October 30, 2026, disclosing a proposed sale of 80,000 shares of common stock valued at $270,272.00, acquired that same day via stock option exercise, along with prior sales totaling 314,064 shares over the preceding three months.